Despite modern advances in cancer medicine, pancreatic cancer survival remains unchanged at just 12%. For the small proportion of patients diagnosed with 'early' (upfront or borderline resectable) disease, recurrences are common, and many recur soon after surgery. Whilst chemotherapy has been shown to increase survival in this cohort, the morbidity of surgery renders many candidates unsuitable for adjuvant treatment. Due to this, and the success of upfront chemotherapy in the advanced setting, use of neoadjuvant chemotherapy has been introduced in patients with upfront or borderline resectable disease. Randomized controlled trials have been conducted to compare upfront surgery to neoadjuvant chemotherapy in this patient cohort, opinions on the ideal upfront treatment approach are divided. This lack of consensus has highlighted the need for biomarkers to assist in clinical decision making. This review analyses the potential diagnostic, prognostic and predictive biomarkers that may assist in the diagnosis and management of early (upfront and borderline resectable) pancreatic cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587199 | PMC |
| http://dx.doi.org/10.1007/s00432-023-05149-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review.
BMC Surg
January 2025
General Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Background And Aim: Hepatocellular carcinoma (HCC) is a highly immunogenic tumor and the third leading cause of cancer-related deaths worldwide with an increasing incidence. Therefore, the combination of immunotherapy with other approaches, such as anti-angiogenic agents and local area therapy, has become a new strategy for HCC treatment.
Methods: We searched PubMed and Web of Science and extracted publications relating to the radiofrequency ablation (RFA) and immunotherapy.
NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration.
BMC Cancer
January 2025
First Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Pancreatic adenocarcinoma (PAAD) is a highly malignant tumor in the digestive system, with an increasing incidence and mortality rate globally. Recent genetic studies have revealed that the abnormal expression and functional dysregulation of various genes are involved in the occurrence and progression of pancreatic cancer. NIPA-like proteins (NIPAs) are expressed in a variety of cancer types, yet the role of NIPAL1 in cancer remains unclear.
View Article and Find Full Text PDFArtificial intelligence methods applied to longitudinal data from electronic health records for prediction of cancer: a scoping review.
BMC Med Res Methodol
January 2025
Leeds Institute of Clinical Trials Research, University of Leeds, Clarendon Way, Leeds, LS2 9NL, UK.
Background: Early detection and diagnosis of cancer are vital to improving outcomes for patients. Artificial intelligence (AI) models have shown promise in the early detection and diagnosis of cancer, but there is limited evidence on methods that fully exploit the longitudinal data stored within electronic health records (EHRs). This review aims to summarise methods currently utilised for prediction of cancer from longitudinal data and provides recommendations on how such models should be developed.
View Article and Find Full Text PDFComparing Operative Outcomes and Resection Quality in Robotic vs Open Pancreaticoduodenectomy: A Meta-analysis of 54,000 Patients.
J Gastrointest Cancer
January 2025
Dow University of Health Sciences, Karachi, Pakistan.
Background: High morbidity and mortality make pancreaticoduodenectomy (PD) one of the most complicated surgical procedures. This meta-analysis aimed to compare the outcomes of robotic pancreaticoduodenectomy (RPD) versus open pancreaticoduodenectomy (OPD).
Method: A comprehensive literature search of PubMed, Cochrane Central, and Google Scholar was conducted from inception to November 2024.
Risk of second primary malignancies among survivors of cutaneous melanoma: A nationwide population-based study in the Republic of Korea.
Sci Rep
January 2025
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
There is limited data on the risk of second primary malignancies (SPMs) in Asian melanoma survivors. This study aimed to identify the risk of SPMs in Asian melanoma survivors. Standardized incidence ratios (SIRs) were calculated for overall and specific SPMs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!